GIPR and Obesity: Also in patients with obesity with or without type 2 diabetes, treatment with the GIPR and GLP1R dual agonists NNC0090-2746 (RG7697)16 or tirzepatide (LY3298176)17,18 showed superior glycemic control and weight loss when compared to selective GLP1R agonism.